Xcel Wealth Management LLC Has $4.84 Million Position in Pfizer Inc. $PFE

Xcel Wealth Management LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 199,636 shares of the biopharmaceutical company’s stock after selling 29,641 shares during the period. Pfizer accounts for approximately 1.4% of Xcel Wealth Management LLC’s holdings, making the stock its 21st biggest holding. Xcel Wealth Management LLC’s holdings in Pfizer were worth $4,839,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the period. Northern Trust Corp boosted its holdings in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock valued at $1,579,340,000 after buying an additional 3,943,397 shares during the last quarter. Amundi grew its position in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Invesco Ltd. raised its stake in Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after buying an additional 838,198 shares during the period. Finally, Deutsche Bank AG boosted its position in Pfizer by 7.0% during the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock worth $715,581,000 after purchasing an additional 1,846,436 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, September 20th. Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.07 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $136.82 billion, a PE ratio of 12.80, a PEG ratio of 0.85 and a beta of 0.55. The firm has a 50 day moving average of $24.59 and a 200-day moving average of $24.18. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.